WallStSmart

AMN Healthcare Services Inc (AMN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1823% more annual revenue ($65.77B vs $3.42B). MRK leads profitability with a 13.6% profit margin vs -0.9%. AMN appears more attractively valued with a PEG of 1.71. AMN earns a higher WallStSmart Score of 62/100 (C+).

AMN

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 6.3Quality: 5.5
Piotroski: 4/9Altman Z: 2.27

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMNUndervalued (+59.9%)

Margin of Safety

+59.9%

Fair Value

$48.75

Current Price

$34.70

$14.05 discount

UndervaluedFair: $48.75Overvalued
MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMN3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
99.9%10/10

Revenue surging 99.9% year-over-year

EPS GrowthGrowth
321.3%10/10

Earnings expanding 321.3% YoY

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

AMN4 concerns · Avg: 3.0/10
PEG RatioValuation
1.714/10

Expensive relative to growth rate

Market CapQuality
$1.33B3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.093/10

Elevated debt levels

Return on EquityProfitability
-4.5%2/10

ROE of -4.5% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AMN

The strongest argument for AMN centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 99.9% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AMN

The primary concerns for AMN are PEG Ratio, Market Cap, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

AMN profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

AMN carries more volatility with a beta of 0.41 — expect wider price swings.

AMN is growing revenue faster at 99.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

AMN scores higher overall (62/100 vs 50/100) and 99.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AMN Healthcare Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

AMN Healthcare Services, Inc. provides healthcare personnel solutions and staffing services to hospitals and healthcare facilities in the United States. The company is headquartered in Dallas, Taxas.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?